31 May 2008

European Medicines Agency
7 Westferry Circus, Canary Wharf
London E14 4HB
UK
qwp@emea.europa.eu


Dear Sir/Madam;

Parenteral Drug Association (PDA) is pleased to provide comments on ICH Topic Q8 Annex, Pharmaceutical Development. PDA is a non-profit international professional association of more than 10,500 member having an interest in the fields of pharmaceutical, biologics, and medical device development, manufacturing and quality.

Our comments were prepared by an expert group of members with practical experience in the area of pharmaceutical/biopharmaceutical development, and are detailed in the attached table. For ease of reference, we have also attached a copy of the Annex with line numbers added.

In addition to our detailed comments we mention the following general points:

- Much of the content of the Annex is a restatement of the parent guideline (ICH Q8, Pharmaceutical Development). It would be helpful to users if the parent guideline and much of the Annex were combined, leaving the actual case studies/examples as the resulting Annex.
- The Annex often suggests that development is either univariate or multivariate. In actual practice, most development activities occur over a continuum, not as an “either/or” approach.
- The general principles described in the Annex apply to biologics and sterile drug products as well as solid dosage forms. However, few examples are provided for these types of products. It would be useful to include illustrative examples for sterile dosage forms.

PDA appreciates the opportunity to support the development of this guidance. Our contact going forward is James Lyda, PDA Europe, lyda@pda.org.

With very best regards,

// (signed)\

Georg Roessling, Ph. D.
Senior Vice President, PDA Europe
roessling@pda.org

Enc.: Q8(R1) with line numbers
Comment Table
Drawing: Knowledge Space

**PDA Final Comments to EMEA - ICH Q8 Annex - 31 May 2008**

<table>
<thead>
<tr>
<th>Line Number*</th>
<th>Comment &amp; Rationale</th>
<th>Proposed Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>General comment</td>
<td>This guidance is an annex to ICH Q8 Pharmaceutical Development and provides further clarification of key concepts outlined in the core guideline. Much of the annex is actually a part of the parent guidance. It may be clearer to users if the parent guidance was expanded to include most of the annex leaving only the actual case studies/examples as an annex.</td>
<td>Combine parent guideline and appendix</td>
</tr>
<tr>
<td>19-20</td>
<td>The wording &quot;An applicant might choose either an empirical approach or a more systematic approach to product development&quot; suggests an either/or approach when it would be more appropriate to characterize the implementation of available tools used in product development as a continuum.</td>
<td>Suggest alternative wording: &quot;Multiple approaches may be followed in product development, ranging from a minimalist approach using experiments on a single variable at a time to a more holistic, systemic, multivariate approach.&quot;</td>
</tr>
<tr>
<td>83-85</td>
<td>An existing draft FDA Guidance also uses the term &quot;Target Product Profile&quot; but with a different meaning (Reference: Guidance for Industry and Review Staff: Target Product Profile - A Strategic Development Process Tool; March 2007).</td>
<td>Clearly define the term &quot;Target Product Profile&quot; in the Glossary section.</td>
</tr>
<tr>
<td>161</td>
<td>It would be useful to include a diagram which illustrates an example of where an input variable or process parameter need not be included in the design space because the particular attribute or parameter has no influence on CQAs.</td>
<td>Either include a diagram/example of where an input variable or process parameter need not be included in the design space or, alternatively, modify the sentence to &quot;no significant effect&quot; A suggested diagram is included as an attachment to our comments.</td>
</tr>
<tr>
<td>162</td>
<td>In the sentence &quot;An input... over the full potential range of operation&quot; requires clear definition especially with regard to the control strategy. The phrase &quot;full potential range of operation&quot; can be interpreted multiple ways. For example, if the focus is on full potential range, this could mean the potential range of the equipment (regardless of the desired process) including the zone of potential failure. If focus is on potential range, it may be intended more narrowly as the proven acceptable range (the upper and lower limits between which the CQAs can still be achieved) or even more narrowly to the extremes of the normal operating range meaning the upper and lower limits between which the parameter or attribute would be routinely controlled during production.</td>
<td>Suggest that &quot;full potential range of operation&quot; be defined in Glossary. Alternatively, suggest wording that may require less interpretation such as &quot;...over the maximum normal operating range that would be used in routine production&quot;.</td>
</tr>
<tr>
<td>Line Number*</td>
<td>Comment &amp; Rationale</td>
<td>Proposed Change</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>210-214</td>
<td>Title of section suggests a comparison/contrast will be made. In fact, little contrast is developed.</td>
<td>Suggest section begin with a definition of design space (from Q8) emphasizing that a design space is characterized by the simultaneous consideration of multiple dimensions and interactions of input variables and process parameters that have been demonstrated to provide assurance of quality.</td>
</tr>
<tr>
<td>232</td>
<td>Stating “A comprehensive pharmaceutical development approach will generate process and formulation understanding that identifies sources of variability” again suggests a binary approach to development when it should be characterized as a continuum. [see comments on lines 19 and 20 above]</td>
<td>Suggest “The more comprehensive the pharmaceutical development approach, the more understanding the manufacturer can have of sources of variability in the processing and formulation of the product.”</td>
</tr>
<tr>
<td>363-364</td>
<td>The phrase “... while keeping other parameters constant, ...” is not required, especially if multivariate analysis was used to determine the operating range. As currently written, the definition is inconsistent with DOE concepts.</td>
<td>Delete the phrase “while keeping other parameters constant”. Alternatively, use the PQRI definition which is, “A characterized range at which a process parameter may be operated within, while producing unit operation material or final product meeting release criteria and Critical Quality Attributes.”</td>
</tr>
<tr>
<td>8</td>
<td>Most of the examples provided relate to solid dosage forms.</td>
<td>As this text is in the introduction to the document, it needs to be clear that the document applies to all dosage forms and not just solid oral products. It would be helpful if other types of dosage forms were be included as examples throughout.</td>
</tr>
<tr>
<td>19</td>
<td>“Empirical” approach*. The word “empirical” is open to interpretation.</td>
<td>Replace the phrase ”empirical approach“ with the phrase “univariate approach”</td>
</tr>
<tr>
<td>20 - 27</td>
<td>The sentences “A more systematic approach to development (also defined as quality by design) can include, for example, incorporation of prior knowledge, results of studies using design of experiments, use of quality risk management, and use of knowledge management (see ICH Q10) throughout the lifecycle of the product. Such a systematic approach can enhance the process to achieve quality and help the regulators to better understand a company's strategy. Product and process understanding can be updated with the knowledge gained over the product lifecycle” are problematic in that companies already use prior knowledge to some extent in developing new products. The systematic approach doesn't enhance the process: it provides information to understand and better define the design space. The purpose is to help the regulators understand a company's control strategy.</td>
<td>Revise to read “The decision to use a systematic approach to development usually involves a combination of methodical review of data from prior knowledge, studies using concepts such as DOE, risk management and formal knowledge management and data handling systems. The use of such a systematic approach will enhance product and process quality thus providing regulators with a better understanding of a company's control strategy. Such information can provide a sound basis for allowing a company greater flexibility in making change control decisions.”</td>
</tr>
<tr>
<td>Line Number</td>
<td>Comment &amp; Rationale</td>
<td>Proposed Change</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>30</td>
<td>The sentence &quot;The degree of regulatory flexibility is predicated on the level of relevant scientific knowledge provided in the registration application,&quot; does not agree with concepts outlined in the parent Q8 document. PDA members' experience suggests that regulatory flexibility is based on three factors: product and process understanding, justification for design space, and effective and robust quality systems.</td>
<td>Revise to read either &quot;The degree of regulatory flexibility is predicated, amongst other factors, on the level of relevant scientific knowledge provided in the registration application.&quot; or &quot;The degree of regulatory flexibility is predicated on the level of relevant scientific knowledge provided in the registration application, the justification presented for design space and the regulatory authority acceptance of process control as determined through application review and inspections.&quot;</td>
</tr>
<tr>
<td>48</td>
<td>Critical quality attributes of the drug substance should be determined- these can then be used as process inputs to the drug product manufacturing process.</td>
<td>Change wording to &quot;Determining the critical quality attributes of the drug substance, excipients, etc…..&quot;</td>
</tr>
</tbody>
</table>
| 59          | The last two bullets (lines 59 and 68) are introduced (on lines 56-57) as being additional to rudimentary product development and the basis of a QbD approach. The aspects that make them unique to QbD should be emphasized. | Suggest alternative wording "Establishment of a design space via a systematic evaluation, understanding and refining of the formulation and manufacturing process, including:"
                                                                                                                                  |
| 76          | Section 2 of the Revision is to describe elements of an enhanced approach to Pharmaceutical Development. Title of section should be accurately described in title.                                                                 | Suggest "Elements of a Systematic Approach to Pharmaceutical Development"
                                                                                                                                  |
| 83          | "Target Product Profile" Is this a universal term?                                                                                                                                                                    | Need to put definition in Glossary.                                                                                                                                  |
| 116-118     | Identifying CQAs in the TPP may not be possible with the limited amount of data initially available.                                                                                                                                 | Revise text to state "Potential critical quality attributes are used to guide the product and process development. These can be identified via TPP or prior knowledge." |
|             | "Risk assessment may be performed at any point in the product life cycle."                                                                                                                                           | "A risk assessment may be performed at any stage in pharmaceutical development and it can be helpful to repeat the risk assessment as information and greater knowledge become available."
                                                                                                                                  |
| 130         | The list of process parameters doesn’t change, but their classification as non-critical, key or critical is made as process knowledge is gained.                                                                       | Rework this sentence to: "The initial list of parameters can be quite extensive, but it can be narrowed by means of prioritizing them for further study (e.g., through a combination of design of experiments, mathematical models, or studies that lead to mechanistic understanding) to achieve a higher level of process understanding."
                                                                                                                                  |
| 233         | "critical sources of variability that can lead to product failure…." Appears to contradict statement that design space does not need to address edge of failure.                                                         | Replace "Critical sources of variability lead to product failure…." with "Critical sources of variability that can impact product quality…"
<pre><code>                                                                                                                              |
</code></pre>
<p>| 269         | &quot;A control strategy can include redundant….&quot; Remove &quot;redundant or&quot; from this sentence.                                                                                                                              | Revise text to &quot;A control strategy can include alternative elements &quot;.                                                                                                                                   |</p>
<table>
<thead>
<tr>
<th>Line Number*</th>
<th>Comment &amp; Rationale</th>
<th>Proposed Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>310-311</td>
<td>“…functional relationships linking material attributes to product CQAs…” Should also include process parameters. “</td>
<td>Change to “…functional relationships linking material attributes and process parameters to product CQAs…”</td>
</tr>
<tr>
<td>381</td>
<td>Use of ” empirical” in the Appendix 1 table (Minimal Approach relating to Overall Pharmaceutical Development) is problematic and may lead to inconsistent interpretations.</td>
<td>Suggest characterizing Minimal Approach as “Data intensive” instead of ”mainly empirical” because QbD is empirical as well, but the experiments may be more complex. In contrast, suggest characterizing QbD approach as “Knowledge intensive”</td>
</tr>
<tr>
<td>381</td>
<td>Using a Table to contrast the Minimal Approach versus the QbD approach suggests an either/or decision when it would be better presented as a continuum of approaches using various tools.</td>
<td>Present as a continuum clarifying that the two extremes are presented but sponsors may choose a variety of approaches in between with science and risk based regulatory approaches a greater possibility as companies invest more in a comprehensive understanding of the processes.</td>
</tr>
<tr>
<td>437-460</td>
<td>For Figures 1 and 2, would be more useful if real examples of what “Parameter 1 and 2” might be, even if hypothetical.</td>
<td>Provide actual examples of what “Parameter 1 and 2” might be.</td>
</tr>
<tr>
<td>24</td>
<td>Since a QbD approach is better described as a continuum, the sentence “Such a systematic approach can enhance…” needs to be modified slightly. Eliminate reference to a particular, single systematic approach”</td>
<td>Suggest “A more systematic approach can enhance…”</td>
</tr>
<tr>
<td>68-70</td>
<td>“…establish an appropriate control strategy which can, for example, include a proposal for design space(s)…..” The control strategy is part of the design space. As such, it shouldn’t necessarily drive how the design space is defined, but rather be an output of it.</td>
<td>Change to: “…establish an appropriate control strategy as part of the proposed design space(s)…..”</td>
</tr>
<tr>
<td>85</td>
<td>Prospective and dynamic</td>
<td>Delete dynamic. Rationale: If it is dynamic then it can’t be prospective because it will change over the entire product lifecycle including after regulatory submission</td>
</tr>
<tr>
<td>Line Number*</td>
<td>Comment &amp; Rationale</td>
<td>Proposed Change</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>152</td>
<td>&quot;The risk assessment and process development experiments described in Section 2.3 can not only lead to an understanding of the linkage and effect of process inputs on product CQAs, but also help identify the variables and their ranges within which consistent quality can be achieved.&quot; The revision is suggested for clarity.</td>
<td>&quot;The risk assessment and process development experiments described in Section 2.3 may lead to an understanding of the linkage and effect of process inputs on product CQAs, and also help identify the variables and their ranges within which consistent quality can be achieved.&quot;</td>
</tr>
<tr>
<td>240</td>
<td>Variability of raw materials is only one factor that can affect product / process quality</td>
<td>Add e.g. so the sentence reads &quot;... will support the control of process parameters so that, e.g., the variability of raw materials...&quot;</td>
</tr>
<tr>
<td>256</td>
<td>Add Proven Acceptable Range (PARs) for process parameters. With all the QbD work performed, PAR should be one of the primary means to achieve control.</td>
<td>Add PARs for process parameters.</td>
</tr>
<tr>
<td>388</td>
<td>Delete “all”. Even the best risk assessment cannot ensure that &quot;all&quot; potential variables are considered.</td>
<td>Delete &quot;all&quot;</td>
</tr>
<tr>
<td>398-417</td>
<td>Ishikawa diagram uses abbreviations without defining what they are.</td>
<td>Suggest providing footnotes describing what the abbreviations P.S., LOD, and RH stand for.</td>
</tr>
<tr>
<td>428</td>
<td>Diagram uses abbreviations without defining what they are</td>
<td>Suggest &quot;(IMC)&quot; in Initial moisture content cell (upper left cell) and so on for &quot;Temp&quot; and &quot;MPS&quot;</td>
</tr>
<tr>
<td>467</td>
<td>Figure 3 could be more useful if it more clearly depicted the interrelationships between design space and the appropriate control space. The text for the Figure suggests that the control limits should be set to avoid excessive impurity formation and excessive particle attrition, but it would be beneficial to depict how the control limits correspond with the design space limits. Are the control limits set at the upper and lower limits of the design space or slightly inside them?</td>
<td>Suggest optimizing the example by including control limits in addition to design space limits. The example may want to illustrate that control limits can be set same as Design space limits or within the upper or lower Design space limit.</td>
</tr>
</tbody>
</table>

*Line numbers refer to FDA version of Q8R (submitted with these comments)*
Input variables or process parameters with no effect on CQAs

All that is known to fail to meet the CQAs

Normal Operating Range
This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

For questions regarding this draft document contact (CDER) Moheb Nasr 301-796-1900, or (CBER) Christopher Joneckis 301-435-5681.

C:\Documents and Settings\thakure\Local Settings\Temporary Internet Files\OLK108\8084dft.doc
1/10/2008
ICH DRAFT: STEP 2

Topic Reference: Q8 (R1)
Subject: Pharmaceutical Development Revision 1
Draft No. 8.1 Dated: 1 November 2007

Rapporteur: Dr. John Berridge (To Step 2)
Address: Pfizer Ltd
Sandwich
Kent
CT13 9NJ
United Kingdom

e-mail: john.berridge@pfizer.com
1. Introduction

This guidance is an annex to ICH Q8 Pharmaceutical Development and provides further clarification of key concepts outlined in the core guideline. In addition, this annex describes the principles of quality by design (QbD). The annex is not intended to establish new standards; however, it shows how concepts and tools (e.g., design space) outlined in the parent Q8 document could be put into practice by the applicant for all dosage forms. Where a company chooses to apply quality by design and quality risk management (ICH Q9, Quality Risk Management), linked to an appropriate pharmaceutical quality system, then opportunities arise to enhance science- and risk-based regulatory approaches (see ICH Q10, Pharmaceutical Quality Systems).

1.1. Approaches to Pharmaceutical Development

In all cases, the product should be designed to meet patients’ needs and the intended product performance. Strategies for product development vary from company to company and from product to product. The approach to, and extent of, development can also vary and should be outlined in the submission. An applicant might choose either an empirical approach or a more systematic approach to product development. An illustration of the potential contrasts of these approaches is shown in Appendix 1. A more systematic approach to development (also defined as quality by design) can include, for example, incorporation of prior knowledge, results of studies using design of experiments, use of quality risk management, and use of knowledge management (see ICH Q10) throughout the lifecycle of the product. Such a systematic approach can enhance the process to achieve quality and help the regulators to better understand a company’s strategy. Product and process understanding can be updated with the knowledge gained over the product lifecycle.

A greater understanding of the product and its manufacturing process can create a basis for more flexible regulatory approaches. The degree of regulatory flexibility is predicated on the level of relevant scientific knowledge provided in the registration application. It is the knowledge gained and submitted to the authorities, and not the volume of data collected, that forms the basis for science- and risk-based submissions and regulatory evaluations. Nevertheless, appropriate data demonstrating that this knowledge is based on sound scientific principles should be presented with each application.

Pharmaceutical development should include, at a minimum, the following elements:

- Defining the target product profile as it relates to quality, safety and efficacy, considering e.g., the route of administration, dosage form, bioavailability, dosage, and stability
- Identifying critical quality attributes (CQAs) of the drug product, so that those product characteristics having an impact on product quality can be studied and controlled
- Determining the quality attributes of the drug substance, excipients etc., and selecting the type and amount of excipients to deliver drug product of the desired quality
- Selecting an appropriate manufacturing process
• Identifying a control strategy

An enhanced, quality by design approach to product development would additionally include the following elements:

• A systematic evaluation, understanding and refining of the formulation and manufacturing process, including:
  
  o Identifying, through e.g., prior knowledge, experimentation, and risk assessment, the material attributes and process parameters that can have an effect on product CQAs
  
  o Determining the functional relationships that link material attributes and process parameters to product CQAs

• Using the enhanced process understanding in combination with quality risk management to establish an appropriate control strategy which can, for example, include a proposal for design space(s) and/or real-time release

As a result, this more systematic approach could facilitate continual improvement and innovation throughout the product lifecycle (See ICH Q10 Pharmaceutical Quality System).

2. Elements of Pharmaceutical Development

The section that follows elaborates, by means of description and example, possible approaches to gaining a more systematic, enhanced understanding of the product and process under development. The examples given are purely illustrative and are not intended to create new regulatory requirements.

2.1 Target Product Profile

A target product profile is a prospective and dynamic summary of the quality characteristics of a drug product that ideally will be achieved to ensure that the desired quality, and hence the safety and efficacy, of a drug product is realised. The target product profile forms the basis of design for the development of the product.

Considerations for the target product profile should include:

• Dosage form and route of administration
• Dosage form strength(s)
• Therapeutic moiety release or delivery and pharmacokinetic characteristics (e.g., dissolution; aerodynamic performance) appropriate to the drug product dosage form being developed
• Drug product quality criteria (e.g., sterility, purity) appropriate for the intended marketed product.

2.2 Critical Quality Attributes

A critical quality attribute (CQA) is a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit,
range, or distribution to ensure the desired product quality. CQAs are generally associated with the drug substance, excipients, intermediates, and drug product. Drug product CQAs include the properties that impart the desired quality, safety, and efficacy. CQAs of solid oral dosage forms are typically those aspects affecting product purity, potency, stability, and drug release. CQAs for other delivery systems can additionally include more product specific aspects, such as aerodynamic properties for inhaled products, sterility for parenterals, and adhesive force for transdermal patches. For drug substances or intermediates, the CQAs can additionally include those properties (e.g., particle size distribution, bulk density) that affect downstream processability.

Drug product CQAs are used to guide the product and process development. Potential drug product CQAs can be identified from the target product profile and/or prior knowledge. The list of potential CQAs can be modified when the formulation and manufacturing process are selected and as product knowledge and process understanding increase. Quality risk management can be used to prioritize the list of potential CQAs for subsequent evaluation. Relevant CQAs can be identified by an iterative process of quality risk management and experimentation that assesses the extent to which their variation can have an impact on the quality of the drug product.

### 2.3 Linking Material Attributes and Process Parameters to CQAs – Risk Assessment

Risk assessment is a valuable science-based process used in quality risk management (see ICH Q9) that can aid in identifying which material attributes and process parameters have an effect on product quality based on prior knowledge and experimental data. Risk assessment tools can be used to identify and rank parameters (e.g., operational, equipment, input material) with potential to have an impact on product quality based on prior knowledge and initial experimental data. For an illustrative example, see Appendix 2. The initial list of potential parameters can be quite extensive, but is likely to be narrowed as process understanding is increased. The list can be refined further through experimentation to determine the significance of individual variables and potential interactions. Once the significant parameters are identified, they can be further studied (e.g., through a combination of design of experiments, mathematical models, or studies that lead to mechanistic understanding) to achieve a higher level of process understanding.

### 2.4 Design Space

The linkage between the process inputs (input variables and process parameters) and the critical quality attributes can be described in the design space. The risk assessment and process development experiments described in Section 2.3 can not only lead to an understanding of the linkage and effect of process inputs on product CQAs, but also help identify the variables and their ranges within which consistent quality can be achieved. These input variables can thus be selected for...
inclusion in the design space.

An explanation should be provided in the application to describe what variables were considered, how they affect the process and product quality, and which parameters were included or excluded in the design space. An input variable or process parameter need not be included in the design space if it has no effect on delivering CQAs when the input variable or parameter is varied over the full potential range of operation. The control of these variables would be under good manufacturing practices (GMP). However, the knowledge gained from studies should be described in the submission.

2.4.2 Defining and describing a design space in a submission

A design space can be defined in terms of ranges of input variables or parameters, or through more complex mathematical relationships. It is possible to define a design space as a time dependent function (e.g., temperature and pressure cycle of a lyophilisation cycle), or as a combination of variables such as principal components of a multivariate model. Scaling factors can also be included if the design space is intended to span multiple operational scales. Analysis of historical data can provide the basis for establishing a design space. Regardless of how a design space is developed, it is expected that operation within the design space will result in a product meeting the defined quality attributes.

Examples of different potential approaches to presentation of a design space are presented in Appendix 2.

2.4.3 Unit operation design space(s)

The applicant can choose to establish independent design spaces for one or more unit operations, or to establish a single design space that spans multiple operations. While a separate design space for each unit operation is often simpler to develop, a design space that spans the entire process can provide more operational flexibility. For example, in the case of a drug product that undergoes degradation in solution before lyophilisation, the design space to control the extent of degradation (e.g., concentration, time, temperature) could be expressed for each unit operation, or as a sum over all unit operations.

2.4.4 Relationship of design space to scale and equipment

When defining a design space, the applicant should keep in mind the type of operational flexibility desired. A design space can be developed at small scale or pilot scale. The applicant should justify the relevance of a design space developed at small or pilot scale to the proposed production scale manufacturing process and discuss the potential risks in the scale-up operation.

If the applicant wishes the design space to be applicable to multiple operational scales, the design space should be described in terms of relevant scale-independent parameters. For example, if a product was determined to be shear sensitive in a mixing operation, the design space could include shear rate, rather than agitation rate. Dimensionless numbers and/or models for scaling also can be included as part of the design space description.

The creation of a design space can be helpful for technology transfer or site changes.
The subsequent regulatory processes will be region-specific.

2.4.5 Design space versus proven acceptable ranges

A combination of proven acceptable ranges does not constitute a design space. However, proven acceptable ranges based on univariate experimentation can provide some knowledge about the process.

2.4.6 Design space and edge of failure

It can be helpful to know where edges of failure could be, or to determine potential failure modes. However, it is not an essential part of establishing a design space.

2.5 Control Strategy

A control strategy is designed to consistently ensure product quality.

The elements of the control strategy discussed in Section P.2 of the dossier should describe and justify how in-process controls and the controls of input materials (drug substance and excipients), container closure system, intermediates and end products contribute to the final product quality. These controls should be based on product, formulation and process understanding and should include, at a minimum, control of the critical parameters and attributes.

A comprehensive pharmaceutical development approach will generate process and formulation understanding that identifies sources of variability. Critical sources of variability that can lead to product failures should be identified, appropriately understood, and managed or controlled. Understanding sources of variability and their impact on downstream processes or processing, intermediate products and finished product quality can provide flexibility for shifting of controls upstream and minimise the need for end product testing. This process understanding, in combination with quality risk management (see ICH Q9), will support the control of process parameters so that the variability of raw materials can be compensated for in an adaptable process to deliver consistent product quality.

This process understanding enables an alternative manufacturing paradigm where the variability of input materials might not need to be tightly constrained. Instead it can be possible to design an adaptive process step (a step that is responsive to the input materials) to ensure consistent product quality.

Enhanced understanding of product performance can justify the use of surrogate tests or support real-time release in lieu of end-product testing. For example, disintegration could serve as a surrogate for dissolution for fast-disintegrating solid forms with highly soluble drug substances. Unit dose uniformity performed in-process (e.g., using weight variation coupled with near infrared (NIR) assay) can enable real-time release and provide an increased level of quality assurance compared to the traditional end-product testing using compendial content uniformity standards.

Elements of a control strategy can include, but are not limited to, the following:
• Control of input material attributes (e.g., drug substance, excipients, primary packaging materials) based on an understanding of their impact on processability or product quality
• Product specification(s)
• Controls for unit operations that have an impact on downstream processing or end-product quality (e.g., the impact of drying on degradation, particle size distribution of the granulate on dissolution)
• In-process or real-time release in lieu of end-product testing
• A monitoring program (e.g., full product testing at regular intervals) for verifying multivariate prediction models.

A control strategy can include redundant or alternative elements, if justified. For example, one element of the control strategy could rely on end-product testing, whereas an additional or alternative element could depend on real-time release using process analytical technology (PAT). The use of these alternative elements should be described in the submission.

Adoption of the principles in this guideline can support the justification of alternative approaches to the setting of specification attributes and acceptance criteria as described in Q6A and Q6B.

2.6 Product Lifecycle Management and Continual Improvement

Throughout the product lifecycle, companies have opportunities to evaluate innovative approaches to improve product quality (see ICH Q10).

For example, once approved, a design space provides the applicant flexibility to optimize and adjust a process as managed under their quality system. A design space is not necessarily static in nature and should be periodically reassessed to ensure that the process is working as anticipated to deliver product quality attributes. For certain design spaces using mathematical models (e.g., chemometrics models of NIR) periodic maintenance could be essential to ensure the models’ performance (e.g., checking calibration), or to update the model based upon additional data. Expansion, reduction or redefinition of the design space could be desired upon gaining additional process information.


Pharmaceutical development information is submitted in Section P.2 of the CTD. Other information resulting from pharmaceutical development studies could be accommodated by the CTD format in a number of different ways and some specific suggestions are provided below. Certain aspects (e.g., product lifecycle management, continual improvement) of this guidance are handled under the applicant’s pharmaceutical quality system (see ICH Q10) and need not be submitted in the registration application.

3.1 Quality Risk Management and Product and Process Development

Quality risk management can be used at many different stages during product and process development and manufacturing implementation. The assessments used to guide and justify development decisions can be included in the relevant sections of
P.2. For example, risk analyses and functional relationships linking material attributes to product CQAs can be included in P.2.1, P.2.2, and P.2.3. Risk analyses linking the design of the manufacturing process to product quality can be included in P.2.3.

3.2 Design Space

As an element of the proposed manufacturing process, the design space(s) can be described in the section of the application that includes the description of the manufacturing process and process controls (P.3.3). If appropriate, additional information can be provided in the section of the application that addresses the controls of critical steps and intermediates (P.3.4). The relationship of the design space(s) to the overall control strategy can be explained in the section of the application that includes the justification of the drug product specification (P.5.6). The product and manufacturing process development sections of the application (P.2.1, P.2.2, and P.2.3) are appropriate places to summarise and describe product and process development studies that provide the basis for the design space(s).

3.3 Control Strategy

The section of the application that includes the justification of the drug product specification (P.5.6) is a good place to summarise the control strategy. The summary should be clear about the various roles played by different components of the control strategy. However, detailed information about input material controls, and process controls should still be provided in the appropriate CTD format sections (e.g., drug substance section (S), control of excipients (P.4), description of manufacturing process and process controls (P.3.3), controls of critical steps and intermediates (P.3.4)).

3.4 Drug Substance Related Information

If drug substance CQAs have the potential to affect the CQAs or manufacturing process of the drug product, some discussion of drug substance CQAs can be appropriate in the pharmaceutical development section of the application (e.g., P.2.1).
4. GLOSSARY

Control Strategy: A planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control. (ICH Q10)

Critical Quality Attribute (CQA): A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.

Critical Process Parameter: A process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to ensure the process produces the desired quality.

Edge of Failure: The boundary to a variable or parameter, beyond which the relevant quality attributes or specification cannot be met.

Proven Acceptable Range: A characterised range of a process parameter for which operation within this range, while keeping other parameters constant, will result in producing a material meeting relevant quality criteria.

Quality by Design: A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.

Real-time release: The ability to evaluate and ensure the acceptable quality of in-process and/or final product based on process data, which typically include a valid combination of assessed material attributes and process controls.
Appendix 1. Differing Approaches to Pharmaceutical Development

Note: This table is intended only to illustrate some potential contrasts between what might be considered a minimal approach and an enhanced approach regarding different aspects of pharmaceutical development and lifecycle management. It is not intended to specifically define the approach. Current practices in the pharmaceutical industry vary and typically lie between these approaches.

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Minimal Approach</th>
<th>Enhanced, quality by design Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Pharmaceutical Development</td>
<td>• Mainly empirical</td>
<td>• Systematic, relating mechanistic understanding of input material attributes and process parameters to drug product CQAs</td>
</tr>
<tr>
<td></td>
<td>• Developmental research often conducted one variable at a time</td>
<td>• Multivariate experiments to understand product and process</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Establishment of design space</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• PAT tools utilised</td>
</tr>
<tr>
<td>Manufacturing Process</td>
<td>• Fixed</td>
<td>• Adjustable within design space</td>
</tr>
<tr>
<td></td>
<td>• Validation primarily based on initial full-scale batches</td>
<td>• Lifecycle approach to validation and, ideally, continuous process verification</td>
</tr>
<tr>
<td></td>
<td>• Focus on optimisation and reproducibility</td>
<td>• Focus on control strategy and robustness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Use of statistical process control methods</td>
</tr>
<tr>
<td>Process Controls</td>
<td>• In-process tests primarily for go/no go decisions</td>
<td>• PAT tools utilised with appropriate feed forward and feedback controls</td>
</tr>
<tr>
<td></td>
<td>• Off-line analysis</td>
<td>• Process operations tracked and trended to support continual improvement efforts post-approval</td>
</tr>
<tr>
<td>Product Specifications</td>
<td>• Primary means of control</td>
<td>• Part of the overall quality control strategy</td>
</tr>
<tr>
<td></td>
<td>• Based on batch data available at time of registration</td>
<td>• Based on desired product performance with relevant supportive data</td>
</tr>
<tr>
<td>Control Strategy</td>
<td>• Drug product quality controlled primarily by intermediate and end product testing.</td>
<td>• Drug product quality ensured by risk-based control strategy for well understood product and process</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Quality controls shifted upstream, with the possibility of real-time release or reduced end-product testing</td>
</tr>
<tr>
<td>Lifecycle Management</td>
<td>• Reactive (i.e., problem solving and corrective action)</td>
<td>• Preventive action</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Continual improvement facilitated</td>
</tr>
</tbody>
</table>
Appendix 2. Illustrative Examples

Example of use of a risk assessment tool.

For example, a cross-functional team of experts could work together to develop an Ishikawa (fishbone) diagram that identifies all potential variables which can have an impact on the desired quality attribute. The team could then rank the variables based on probability, severity, and detectability using failure mode effect analysis (FMEA) or similar tools based on prior knowledge and initial experimental data. Design of experiments or other experimental approaches could then be used to evaluate the impact of the higher ranked variables, to gain greater understanding of the process, and to develop a proper control strategy.

Ishikawa Diagram
Example of depiction of interactions

The figure below depicts the effect of interactions, or lack thereof, between three process parameters on the level of degradation product Y. The figure shows a series of two-dimensional plots showing the effect of interactions among three process parameters (initial moisture content, temperature, mean particle size) of the drying operation of a granulate (drug product intermediate) on degradation product Y. The relative slopes of the lines or curves within a plot indicate if interaction is present. In this example, initial moisture content and temperature are interacting; but initial moisture content and mean particle size are not, nor are temperature and mean particle size.

![Graph showing interactions between initial moisture content, temperature, and mean particle size](image-url)
Illustrative examples of presentation of design space

Figure 1: Design space described with the aid of response surface plot (Figure 1a) or contour plot (Figure 1b) and defined by non-linear (Figure 1c) or linear combination (Figure 1d) of process parameter ranges. In this example, the effects of the two parameters are additive, but the two parameters do not interact.

Figure 1a: Response surface plot of dissolution as a function of two parameters of a granulation operation. Dissolution above 80% is desired.

Figure 1b: Contour plot of dissolution from example 1a.

Figure 1c: Design space for granulation parameters, defined by a non-linear combination of their ranges, that delivers satisfactory dissolution (i.e., >80%). In this example, the design space can be optionally expressed by equations that describe the boundaries, i.e.,
- Parameter 1 has a range of 41 to 56
- Parameter 2 has a lower limit of 0 and an upper limit that is a function of Parameter 1

Figure 1d: Design space for granulation parameters, defined by a linear combination of their ranges, that delivers satisfactory dissolution (i.e., >80%). This design space is a subset of the non-linear design space from Example 1c, and can be optionally expressed as the following:
- Parameter 1 has a range of 44 to 53
- Parameter 2 has a range of 0 to 1.1

Where multiple parameters are involved, the design space can be presented for two parameters, in a manner similar to the examples shown above, at different values (e.g., high, middle, low) within the range of the third parameter, the fourth parameter, and so on. A stacked plot of these design spaces can be considered, if appropriate.
Figure 2: Design space determined from the common region of successful operating ranges for multiple CQAs. The relations of two CQAs, i.e., friability and dissolution, to two process parameters of a granulation operation are shown in Figures 2a and 2b. Figure 2c shows the overlap of these regions and the maximum ranges of the potential design space.

Figure 2a: Contour plot of friability as a function of Parameters 1 and 2.

Figure 2b: Contour plot of dissolution as a function of Parameters 1 and 2.

Figure 2c: Potential process design space, comprised of the overlap region of design ranges for friability and or dissolution.
Figure 3: The design space for a drying operation that is dependent upon the path of temperature and/or pressure over time. The end point for moisture content is 1-2%. Operating above the upper limit of the design space can cause excessive impurity formation, while operating below the lower limit of the design space can result in excessive particle attrition.